Search results
Results from the WOW.Com Content Network
Phenylacetone, also known as phenyl-2-propanone, is an organic compound with the chemical formula C 6 H 5 CH 2 COCH 3. It is a colorless oil that is soluble in organic solvents. It is a mono-substituted benzene derivative, consisting of an acetone attached to a phenyl group. As such, its systematic IUPAC name is 1-phenyl-2-propanone.
Propiophenone can be prepared by Friedel–Crafts reaction of propanoyl chloride and benzene.It is also prepared commercially by ketonization of benzoic acid and propionic acid over calcium acetate and alumina at 450–550 °C: [1]
3,4-Methylenedioxyphenylpropan-2-one [1] or piperonyl methyl ketone (MDP2P or PMK) is a chemical compound consisting of a phenylacetone moiety substituted with a methylenedioxy functional group. It is commonly synthesized from either safrole (which, for comparison, is 3-[3,4-(methylenedioxy)phenyl]-2-propene) or its isomer isosafrole via ...
How to make non-Newtonian liquid: 2.5 cups of corn starch. 1 cup of water. 1 tablespoons of paint. After all ingredients are in a medium-sized mixing bowl, mix until well incorporated.
Methyl isobutyl ketone (MIBK, 4-methylpentan-2-one) is an organic compound with the condensed chemical formula (CH 3) 2 CHCH 2 C(O)CH 3. This ketone is a colourless liquid that is used as a solvent for gums, resins, paints, varnishes, lacquers, and nitrocellulose.
Propionaldehyde or propanal is the organic compound with the formula CH 3 CH 2 CHO. It is the 3-carbon aldehyde. It is a colourless, flammable liquid with a pungent and fruity odour. It is produced on a large scale industrially.
The cumene process (cumene-phenol process, Hock process) is an industrial process for synthesizing phenol and acetone from benzene and propylene. The term stems from cumene (isopropyl benzene), the intermediate material during the process. It was invented by R. Ūdris and P. Sergeyev in 1942 (USSR), [1] and independently by Heinrich Hock in ...
A mere 2.5 percent of all primary care doctors have gone through the certification process. “I cannot say it enough,” said then-Sen. Carl Levin (D-Mich.) at the meeting. “Unless primary care physicians can identify the disease of addiction and know how to intervene, we will make slower progress than we should,” Levin said.